Cryoglobulinemia medical therapy

Revision as of 00:00, 30 April 2018 by Feham Tariq (talk | contribs)
Jump to navigation Jump to search

Cryoglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cryoglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cryoglobulinemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cryoglobulinemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cryoglobulinemia medical therapy

CDC on Cryoglobulinemia medical therapy

Cryoglobulinemia medical therapy in the news

Blogs on Cryoglobulinemia medical therapy

Directions to Hospitals Treating Cryoglobulinemia

Risk calculators and risk factors for Cryoglobulinemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Feham Tariq, MD [2]

Overview

Medical Therapy

The medical treatment of cryoglobulinemia depends on the underlying etiology, nature and progression of the disease. The main indication for therapy is progressive end organ disease affecting the kidneys, skin, gastrointestinal system, central nervous system and the extremities.

Acute Pharmacotherapies

  • Outside of the acute setting, immunosuppresive agents are thought to worsen the course of MC associated with HCV.
    • Interferon-alfa and ribavirin have been used in combination.
  • MC response, predictably, was related to the response rate of the underlying HCV to these agents.
  • Ribavirin should not be used in patients with glomerular filtration rate (GFR) <50 cc/min.

References


Template:WikiDoc Sources